Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 12737866.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
An increase in invasive Hib disease incidence in the UK has coincided with the distribution of combination vaccines that contain acellular pertussis (DTaP-Hib). These vaccines have been associated with reduced immunogenicity of the Hib component, although there is little agreement on the clinical relevance of this finding. We retrospectively compared vaccine formulations given to fully vaccinated Hib cases with those administered to fully immunised age-matched controls using conditional logistic regression. More cases than controls received all three doses of their infant primary course as DTaP-Hib, compared with two or three doses of another Hib vaccine (conditional odds ratio 6.77 [95% CI 3.26-14.07]).
Medical subject headings
- Diphtheria-Tetanus-Pertussis Vaccine
- Haemophilus Vaccines
- Haemophilus influenzae type b
- Hepatitis B Vaccines
- Meningitis, Haemophilus